POTD: Dextrose Containing Fluids

During my very brief stint as your TR I have received two separate requests to discuss dextrose-containing fluids so for today’s POTD we’re going to review the use of these dextrose fluids based on their various formulations. 

Dextrose containing fluids are often used in the management of hypoglycemia. Hypoglycemia is defined as an abnormally low plasma glucose level, typically below 60 or 70 mg/dl in adults. Oral repletion is preferred in patients who are awake, alert, and able to swallow. However, for patients with severe hypoglycemia or altered mental status, you likely need to give intravenous dextrose containing fluids. These fluids are commonly referred to by the percent of glucose present in the solution, such as D50, D10, D5, etc.

D50 contains 25g of glucose in 50mL of water. This usually comes as a prefilled syringe and is commonly referred to as “an amp of D50.” Admittedly this is the dextrose containing fluid I find myself ordering the most for acute hypoglycemia. It is readily available (can be found in any of the ED omnicells) and provides a quick bolus of glucose with about five times the amount of glucose present in a normal adult’s blood. However, D50’s hypertonic nature increases the risk of vascular and tissue damage. If administered into a small vein D50 can be irritating and may cause thrombophlebitis. Additionally, it is also prone to extravasation from the vein leading to skin irritation and, in severe cases, local scarring or skin necrosis. Given these complications, some people advocate for the use of D10 instead.

D10 often comes as 10g of glucose in 100mL of fluid. This fluid has a lower osmolarity compared to D50, which reduces the risk of extravasation and thrombophlebitis. The lower concentration of D10 also allows for easier titration to ensure the patient becomes normoglycemic without overshooting and causing hyperglycemia. From my googles and discussions, the primary defense against using D10 in acute hypoglycemia seems to be a concern about the time required to give D10 as compared to D50. However, it’s important to note that one amp of D50 should be infused over 2-3 minutes to avoid extravasation. Studies show that a 200mL bolus of D10 (containing 20g of glucose) can be administered via pressure bag and will enter the patient’s bloodstream as quickly as slow pushing an amp of D50 (containing 25g of glucose). At Maimo, D10 can be found in the ED pharmacy, but after pharmacy leaves at night you would have to get it sent down from central pharmacy (unless you’re in peds, where there is usually a few bag of D10). 

Speaking of pediatrics… the treatment of hypoglycemia is slightly different in children. To minimize vascular complications associated with highly concentrated dextrose fluids, we opt for using weight based volumes of more dilute fluids, such as D10 or D25.

The general rule of thumb is neonates and infants (less than 1 year old) should get D10, while toddlers and children (1-8 years old) should get D25. Adolescents (greater than 8 years old) can be given D50. Regardless of the dextrose concentration, the volume administered should provide 0.5g dextrose per kg. To conveniently calculate the dose in milliliters, we use the “Rule of 50” – multiply the type of dextrose solution by a factor of 5, 2, or 1 (ml/kg) to give a total of 50.

  • D10: 10 x 5 = 50, so give 5ml/kg

  • D25: 25 x 2 = 50, so give 2ml/kg

  • D50: 50 x 1 = 50, so give 1ml/kg

Overall these rules can be summarized as:

  • Neonates and infants <1 YO, give D10 at 5 ml/kg

  • Toddlers and children 1-8 YO, give D25 at 2ml/kg

  • Adolecents > 8YO, give D50 at 1ml/kg

Of note, we do not have D25 fluids in the Maimo ER so usually I’ve seen people give D10 regardless of the patient’s age. Though you can always get D25 from PICU or central pharmacy in a pinch you can always make it out of an amp of D50. To make D25, discard 25mL from the D50 ampule and then add 25mL of NS or sterile water back into the ampule. Similarly, to make D10, discard 40mL from the D50 ampule and replace it with 40mL of NS or sterile water.

And last but not least, D5 is another fluid option with 5g of dextrose in 100ml of fluid. This is another commonly used dextrose-containing fluid that can be found in all the ED Omni cells. However, this fluid is too dilute to be recommended as a bolus treatment for acute hypoglycemia. Instead, where it shines is as a maintenance fluid to maintain normoglycemia and prevent rebound hypoglycemic events.

 

Sources:

https://www.emdocs.net/em3am-hypoglycemia/

https://www.aliem.com/d50-vs-d10-severe-hypoglycemia-emergency-department/

https://pemcincinnati.com/blog/521-50-dextrose-volume-hypoglycemia/

 · 

POTD: Ultrasound Guided Access

A few weeks ago one of our lovely interns asked me “how do you know when to put in an ultrasound IV versus a midline?” To which I replied, “blood pressure and vibes.” But in hindsight… I fear that may not be the most helpful answer so I’m going to spend today’s POTD reviewing the various intravenous catheters we place under ultrasound guidance and when to use them.

Ultrasound-guided IV: This is your typical peripheral catheter placed into a vein (usually the upper arm) for the purpose of blood draws, medication administration, and contrast infusion. These are indicated in patients who have poor vasculature such that our excellent nurses can’t obtain IV access. You can theoretically place any size catheter, but most often you will use an 18g or 20g. 

Midline: An intermediate between an ultrasound guided IV and a central line. Like an ultrasound IV, they are placed in a large vein in the patient’s upper arm. However, it’s longer and has thicker walls than a peripheral IV catheter which reduces the risk of the line getting dislodged. Thus, midlines can be used for medications with high risk for extravasation (i.e. vasopressors, calcium chloride, hypertonic saline). When placing a midline, you should maintain a sterile field as these can be left in for weeks. At Maimo we have both single lumen (3Fr with one 18g channel x 10cm long) and double lumen (4 Fr with two 18g channels x 20cm long) midlines. Single lumens are slightly easier, faster, and less painful to insert. Double lumens allow you to give multiple medications simultaneously. Before inserting a midline assess the current and anticipated needs of your patient to decide if they need a single or double lumen. Some people opt to place a midline in any north side patient who is ill-appearing and definitely getting admitted to save you and the patient from future pokes.

Now here’s where things can get confusing because we use multiple terms to describe very similar procedures so stick with me here…

Central Venous Line: Triple lumen catheter placed into the internal jugular, subclavian, or femoral vein. These catheters are versatile and can be used for various purposes, including medication administration, blood draws, fluid resuscitation, and hemodynamic monitoring. They are useful for patients who require more secure and definitive access compared to a midline, or when a midline can’t obtained. Triple lumen CVCs are typically 20cm long and have a 7Fr diameter, with one 16g and two 18g channels.  

Trialysis: Another triple lumen catheter placed into the internal jugular, subclavian or femoral vein. This catheter is unique from the above CVC due to its larger channels which have a 13Fr diameter, with one 17g and two 12g channels. The larger diameter allows the trialysis to be used for all the typical central line indications plus dialysis.

Cordis: Large bore single lumen catheter placed in the internal jugular, subclavian, or femoral vein. Unlike the CVC and trialysis, the cordis is shorter (10cm long) with a larger diameter (9Fr with one 11g channel). This allows the cordis to have a much higher flow rate compared to other lines, so it is placed in patients requiring rapid transfusion, usually of large volume blood products. 

 · 

POTD: Tamiflu Tuesday

Respiratory season is here in Brooklyn, and with it comes the return of influenza. Just last week, we saw a significant increase (53%) in the number of positive influenza tests compared to the previous week. While the ED volume may make it seem like we’re at the peak, unfortunately, this graph from the New York State Department of Health suggests that we’re only just beginning. 

With the influx of influenza-positive patients into the ED, you may to wonder if there’s anything we can do for them. Tamiflu, also known as Oseltamivir, is a drug that can help alleviate the symptoms of influenza. This drug works by inhibiting the neuraminidase enzyme of the influenza virus, preventing its replication in the body. I personally like this graphic that perfectly summarizes the mechanism of action with a giant red X.

To Tamiflu or not to Tamiflu?

But of course, some things are simply too good to be true and the lore surrounding Tamiflu is rife with controversy.

To make a long story short, Tamiflu first entered the market in 1999 and received substantial support from the CDC and WHO. It even made it onto the World Health Organization’s List of Essential Medicines from 2009 to 2017. This support was based on multiple pharmaceutical-sponsored trials that showed a ~1.5-day reduction in influenza symptoms and a reduction in secondary complications, such as hospitalizations and pneumonia. However, in a shocking turn of events, the pharmaceutical companies (namely Roche) who sponsored these trials didn’t even provide the authors with access to the data but instead simply informed them of the data’s purported findings.

This discovery brought all the data into question. Since then, numerous studies have been conducted to assess the true efficacy of Tamiflu. I’ll list some of these studies below for your review, but the bottom line is that the data supporting Tamiflu’s benefits is, at best, lackluster.

Benefits of Tamiflu:

  • Reduces the duration of symptoms by up to 36 hours (but more realistically around 17-24 hours) when started within 48 hours of symptom onset.

  • Decreases the likelihood of contracting the flu by approximately 50-80% when used as a post-exposure prophylaxis medication within 48 hours of exposure.

Risks of Tamiflu:

  • Nausea, vomiting, diarrhea, and/or headache occur in up to 17% of patients.

  • Neuropsychiatric events (including confusion, delirium, hallucinations) have been reported.

  • The cost of Tamiflu is around $60 for patients without insurance.

The saga and controversy of Tamiflu could go on much longer, but I’ll wrap it up here.

TLDR: The data for Tamiflu suggests a very modest reduction in the duration of symptoms (only about half to one full day) without a statistically significant reduction in complications such as hospitalizations or pneumonia. There are notable risks, including gastrointestinal distress and reports of neuropsychiatric events in children. Instead just get your flu shot.

Sources:

https://www.health.ny.gov/diseases/communicable/influenza/surveillance/2024-2025/flu_report_current_week.pdf

https://rebelem.com/the-alic4e-trial-oseltamivir-usual-care-vs-usual-care-alone/

https://www.bmj.com/tamiflu

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215903

https://first10em.com/tamiflu-doesnt-work/

https://rebelem.com/the-tamiflu-debacle/

 

Tamiflu Trials:

Jefferson T et al. Oseltamivir for Influenza in Adults and Children: Systematic Review of Clinical Study Reports and Summary of Regulatory Comments. BMJ 2014. PMID: 24811411

Krumholz HM et al. Neuraminidase Inhibitors for Influenza: The Whole Truth and Nothing but the Truth. BMJ 2014. PMID: 24811413

Okoli GN et al. Use of Neuraminidase Inhibitors for Rapid Containment of Influenza: A Systematic Review and Meta-Analysis of Individual and Household Transmission Studies. PLOS One 2014.PMID: 25490762

Qiu S et al. Effectiveness and Safety of Oseltamivir for Treating Influenza: An Updated Meta-Analysis of Clinical Trials. Infectious Diseases 2015. PMID: 26173991

Heneghan CJ et al. Neuraminidase Inhibitors for Influenza: A Systematic Review and Meta-Analysis of Regulatory and Mortality Data. Health Technology Assessment 2016. PMID: 27246259

 ·